These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 32565352)

  • 1. A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
    Ye L; Ke M; You X; Huang P; Lin C
    J Pharm Sci; 2020 Sep; 109(9):2909-2918. PubMed ID: 32565352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations.
    Guo L; Zhu X; Zhang L; Xu Y
    Ther Adv Drug Saf; 2023; 14():20420986231220222. PubMed ID: 38157240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling of Lacosamide in Patients With Hepatic and Renal Impairment and Pediatric Populations to Support Pediatric Dosing Optimization.
    Zhu X; Guo L; Zhang L; Xu Y
    Clin Ther; 2024 Mar; 46(3):258-266. PubMed ID: 38369451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations.
    Wang R; Wang T; Han X; Chen M; Li S
    Xenobiotica; 2024 Mar; 54(3):116-123. PubMed ID: 38344757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous ibuprofen pharmacokinetics between Caucasian and Chinese populations using physiologically based pharmacokinetics modeling and simulation.
    Jin Y; Zhang M; Di X; Qi X; Zheng L; Wang Z
    Eur J Pharm Sci; 2023 Dec; 191():106587. PubMed ID: 37734467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
    Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
    Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.
    Zhang Y; Zhao S; Wang C; Zhou P; Zhai S
    Front Pharmacol; 2021; 12():636097. PubMed ID: 33815119
    [No Abstract]   [Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.
    Gao D; Wang G; Wu H; Ren J
    Sci Rep; 2023 Sep; 13(1):16027. PubMed ID: 37749178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.
    Hornik CP; Wu H; Edginton AN; Watt K; Cohen-Wolkowiez M; Gonzalez D
    Clin Pharmacokinet; 2017 Nov; 56(11):1343-1353. PubMed ID: 28290120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations.
    Shen C; Shao W; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
    CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1001-1015. PubMed ID: 37170680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Mechanistic Physiologically-Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers.
    Zhang X; Lumen A; Wong H; Connarn J; Dutta S; Upreti VV
    Clin Pharmacol Ther; 2024 Mar; 115(3):457-467. PubMed ID: 37746860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of Ustekinumab in pediatric patients with inflammatory bowel disease.
    Cai X; Wu W; Guo G; Chen J; Xu J; Lin W; Huang P; Lin C; Lin R
    Eur J Pharm Sci; 2024 Aug; 199():106807. PubMed ID: 38797440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia.
    Kalsoom S; Rasool MF; Imran I; Saeed H; Ahmad T; Alqahtani F
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics.
    Wang Q; Yan Y; Li S; Yi H; Xie F
    Br J Clin Pharmacol; 2024 Jul; ():. PubMed ID: 38958222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model.
    Zhang M; Zhang S; Yu Z; Yao X; Lei Z; Yan P; Wu N; Wang X; Hu Q; Liu D
    Eur J Pharm Sci; 2023 Oct; 189():106553. PubMed ID: 37532063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof-of-Concept Application of Liquid Biopsy in Renal Impairment.
    Rostami-Hodjegan A; Al-Majdoub ZM; von Grabowiecki Y; Yee KL; Sahoo S; Breitwieser W; Galetin A; Gibson C; Achour B
    Clin Pharmacol Ther; 2024 Sep; 116(3):814-823. PubMed ID: 38738484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model informed drug development: HSK21542 PBPK model supporting dose decisions in specific populations.
    Zhang M; Lei Z; Yao X; Zhang L; Yan P; Wu N; Chen M; Zhang F; Liu D
    Eur J Pharm Sci; 2024 May; 196():106763. PubMed ID: 38599505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulation of optimal dose regimens of photoactivated curcumin for antimicrobial resistance pneumonia in COVID-19 patients: A modeling approach.
    Sae-Heng T; Na-Bangchang K
    Infect Dis Model; 2023 Jun; 8(3):783-93. PubMed ID: 37361409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
    Zhou J; You X; Ke M; Ye L; Wu W; Huang P; Lin C
    J Pharm Sci; 2021 Apr; 110(4):1853-1862. PubMed ID: 33556385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.
    Heimbach T; Chen Y; Chen J; Dixit V; Parrott N; Peters SA; Poggesi I; Sharma P; Snoeys J; Shebley M; Tai G; Tse S; Upreti VV; Wang YH; Tsai A; Xia B; Zheng M; Zhu AZX; Hall S
    Clin Pharmacol Ther; 2021 Aug; 110(2):297-310. PubMed ID: 33270249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.